A Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Phase 1 Study of AK002, a Novel Siglec-8 Selective Monoclonal Antibody, in Healthy Subjects
Henrik Rasmussen(University of Oslo), Christopher Bebbington(Curtin University), Nenad Tomašević(Regenxbio (United States)), Alan T. Chang(Allakos (United States))
Cited by 26
Related Papers
Chimeric Receptors Providing Both Primary and Costimulatory Signaling in T Cells from a Single Gene Product
|The Journal of Immunology|1998|546
Anti–Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis
|New England Journal of Medicine|2020|263
GM-CSF–dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia
|Blood|2013|155
An Engineered Human Antibody Fab Fragment Specific for <i>Pseudomonas aeruginosa</i> PcrV Antigen Has Potent Antibacterial Activity
|Infection and Immunity|2008|122
AK002, a Humanized Sialic Acid-Binding Immunoglobulin-Like Lectin-8 Antibody that Induces Antibody-Dependent Cell-Mediated Cytotoxicity against Human Eosinophils and Inhibits Mast Cell-Mediated Anaphylaxis in Mice
|International Archives of Allergy and Immunology|2019|111